WOBURN, Mass., May 16 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that the company has been awarded the 2007 Technology Innovation Award from Frost & Sullivan. VisEn received the Award for its portfolio of Fluorescence In Vivo Imaging Probes, demonstrating technological superiority in the category of molecular imaging. VisEn develops and markets its Fluorescence In Vivo Imaging Probes to enable expanded areas of disease research, facilitated drug development, and going forward, improved clinical practice in personalized medicine.
“VisEn Medical has developed the industry’s most comprehensive in vivo imaging product lines, affording researchers unparalleled versatility and functionality in observing, measuring and quantifying ranges of biological activity within living systems,” said Subha B. Basu, Ph.D., Industry Analyst at Frost & Sullivan’s Healthcare Medical Imaging group. “The fact that one company provides such a breadth and robustness of fluorescence molecular imaging product offerings conveys great value on VisEn as a trusted source of molecular imaging solutions in both academic and pharmaceutical settings. Importantly, because of VisEn’s heritage and focus on clinical medicine, the potential applications for these molecular imaging technologies in the future are expected to extend well beyond pre-clinical research and drug development, and into clinical trial and therapeutic settings as well.”
VisEn’s imaging probes are designed to provide a robust range of biologically specific imaging readouts in vivo. VisEn now offers over 20 different molecular probes for imaging key biologic processes and pathways in vivo, with more expected to be launched this year. VisEn probes are designed to be compatible with a range of fluorescence imaging systems, including planar fluorescence systems, intravital microscopes, and VisEn’s FMT(TM) (Fluorescence Molecular Tomography) imaging system. FMT is VisEn’s proprietary in vivo imaging platform capable of providing true quantification of fluorescence data in vivo.
“VisEn is gratified to have received this important industry recognition of our fluorescence molecular imaging technologies,” said Kirtland G. Poss, President and CEO of VisEn Medical. “We owe this success in large part to our strong collaborations with leading academic institutions and pharmaceutical companies worldwide-partnerships that directly contribute to the design, development and optimization of novel imaging probes for use within the pharmaceutical industry and medical research community. By enabling true data linkages between biologic profiling, pre-clinical animal models and clinical research and medicine, we believe that our technology platforms and approach to molecular imaging will continue to enhance all aspects of disease research, drug development, and ultimately patient care going forward.”
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.awards.frost.com.
About Best Practices
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing the industry’s highest performing fluorescence molecular imaging technology platforms, from research through medicine. VisEn also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. The Company recently announced a multi-year joint research and development program with Merck & Co to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group. For further information please visit www.visenmedical.com.
VisEn Medical, Inc.
CONTACT: Kirtland G. Poss, President and CEO of VisEn Medical, Inc.,+1-781-932-6875, ext. 301
